Milestone Pharmaceuticals Inc — Balance Sheet (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 149.97 M119.85 M74.48 M75.23 M75.5 M Total liabilities 6.86 M7.25 M8.13 M58.45 M62.35 M Total equity 143.12 M112.6 M66.35 M16.77 M13.15 M Total liabilities & shareholders' equities 149.97 M119.85 M74.48 M75.23 M75.5 M Total debt ————— Net debt —————

Nachrichten

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Aptar liefert Nasenspray-System für neu zugelassene Herztherapie

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

Milestone Pharmaceuticals: TD Cowen stuft Aktie nach FDA-Zulassung auf ’Buy’ hoch

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

FDA-Zulassung für Herz-Nasenspray beflügelt Milestone-Aktie

Milestone stock soars after FDA approves first self-administered PSVT spray

Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday? - Milestone Pharmaceuticals (NASDAQ:MIST)